The health risks of too much sugar have been made clear, but the billion-dollar global market to supply it is thriving. Sales of sweet treats remain strong, and waistlines keep expanding.
Could weight-loss drugs now succeed where governments, scientists and doctors have failed: crushing demand for sugar? So-called glucagon-like peptide-1 receptor agonists (GLP-1s) contained in such drugs as Wegovy, Mounjaro and Ozempic curb users’ appetites and are being hailed as game changers for tackling obesity and potentially a range of other conditions, from diabetes to addiction. They could also lead to an upheaval in sugar markets. Fears that Americans on GLP-1s will stop buying treats have already spooked businesses and investors. Mondelez and PepsiCo stocks took a hit after Walmart chief executive John Furner reported that customers on these drugs were buying fewer groceries. Hershey has also acknowledged experiencing a “mild impact” on sales, attributed to the growing use of GLP-1 medications. Sugar traders, for now, are brushing off concerns about weight-loss drugs’ potential to dent demand. Perhaps they’re battle-hardened — decades of sugar-is-bad campaigns have not made a dent in global consumption, which has quadrupled in the past 60 years, according to Professor Paul Behrens of the British Academy. Sweet treats still fly off the shelves in most markets, and until recently sugar prices have been riding high on weather woes and rising production costs. There are other reasons for traders’ nonchalance. So far, Ozempic and other drugs are pricey and only available to a small segment of wealthy consumers in developed countries. Even if these appetite-suppressing drugs do start reducing demand, the thinking goes, it’ll be a slow burn, giving markets and sugar producers plenty of time to adjust. But could this confidence be misplaced? Weight-loss drugs do work in curbing appetites